The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use disorder. The app can be downloaded to a patient’s mobile device with a prescription from his/her doctor to use while participating in an outpatient treatment program under the care of a health care professional, in conjunction with treatment that includes buprenorphine and contingency management. “As part of our efforts to address the misuse and abuse of opioids, we’re especially focused on new tools and therapies that can help more people with opioid use disorder successfully treat their addiction,” said FDA Commissioner Scott Gottlieb, M.D. “Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in contributing to these treatment efforts.”

Related News Articles

Headline
The Substance Abuse and Mental Health Services Administration will launch a three-part virtual learning series on recovery supports for people considering or…
Headline
Drug overdose deaths declined 5.1% in 2018 to about 68,000, according to preliminary data from the Centers for Disease Control and Prevention.
Headline
Under a new Centers for Medicare…
Headline
Six health care organizations in rural North Carolina communities will share $1.2 million in federal grant funds to strengthen and expand their response to…
Headline
The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic will host a free public webinar July 22 at 3 p.m. ET on best…